VERACYTE, INC. (VCYT)
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Sector: Services-Medical Laboratories
Industry: Medical - Diagnostics & Research
Veracyte, Inc.
Trials need funding. See this company's dilution risk and cash position.
- ObservationalRecruiting
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
-
Pulmonary Nodule, Solitary, Lung Cancer
NCT06426628Enrollment2,400StartJul 2022Primary CompletionDec 2024est.CompletionMar 2027est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Observational | Recruiting | - | NCT06426628 |